Condition
Viral Gastroenteritis Due to Rotavirus
Total Trials
5
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 3 (1)
P 4 (1)
Trial Status
Unknown3
Completed1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02941107Phase 4Active Not RecruitingPrimary
Optimising Rotavirus Vaccine in Aboriginal Children
NCT01633190UnknownPrimary
Canadian Rotavirus Surveillance Through the Immunization Monitoring Program Active (IMPACT)
NCT01305109Phase 3UnknownPrimary
A Phase III Clinical Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E
NCT01472575UnknownPrimary
Impact of Rotavirus Vaccine Introduction for South Australian Children
NCT01328925Phase 2Completed
Efficacy Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children
Showing all 5 trials